Green Cross Corp (GC Biopharma) stock (KR7006280002): Biopharma innovator with plasma focus

Green Cross Corp (GC Biopharma), a leading South Korean biopharmaceutical firm, specializes in plasma-derived therapies and vaccines. US investors track its Nasdaq listing and growth in biologics amid global demand for immune products.

Green Cross Corp (GC Biopharma) continues to draw attention from international investors as a key player in plasma-derived medicines and recombinant vaccines. The company reported steady progress in its core plasma fractionation business in its latest filings, with operations spanning South Korea and global markets. This positions GC Biopharma as a notable name for US portfolios seeking exposure to Asian biotech innovation.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Green Cross Corp (GC Biopharma)
• Sector/industry: Biopharmaceuticals
• Headquarters/country: South Korea
• Core markets: Asia, global plasma products
• Key revenue drivers: Plasma therapies, vaccines
• Home exchange/listing venue: Korea Exchange (KRX)
• Trading currency: KRW

Green Cross Corp (GC Biopharma): core business model

Green Cross Corp (GC Biopharma) operates as a biopharmaceutical company focused on developing, manufacturing, and distributing plasma-derived products, vaccines, and other biologics. Founded in 1982 and rebranded from Green Cross in 2021, it leverages advanced plasma fractionation technology to produce immunoglobulins, albumin, and coagulation factors essential for treating immune deficiencies and bleeding disorders. The firm's integrated model includes research, production at multiple facilities in South Korea, and distribution worldwide, serving hospitals and clinics with high-demand therapies.

This business approach emphasizes self-sufficiency in plasma sourcing and processing, reducing reliance on imports amid global supply constraints. GC Biopharma's portfolio also extends to recombinant vaccines and antidotes, supporting its resilience in diverse therapeutic areas. For US investors, the company's scale in Asia's biologics market offers indirect exposure to rising demand for plasma products in North America.

Main revenue and product drivers for Green Cross Corp (GC Biopharma)

The primary revenue engine for Green Cross Corp (GC Biopharma) remains its plasma derivative segment, which accounts for the majority of sales through products like immune globulin intravenous (IGIV) and hyperimmune globulins. In fiscal year 2024 results published in February 2025, plasma products generated substantial growth driven by expanded production capacity at its Iksan plant, according to GC Biopharma IR as of 02/2025. Vaccines contribute via offerings such as the recombinant hepatitis B vaccine, while newer biosimilars bolster diversification.

Key growth drivers include capacity expansions and international partnerships, with exports to over 20 countries enhancing margins. The company's focus on high-value plasma therapies aligns with global aging populations increasing immunoglobulin needs. US investors note GC Biopharma's role in stabilizing supply chains for biologics that complement domestic production shortages.

Industry trends and competitive position

The biopharma sector, particularly plasma fractionation, faces tailwinds from rising immunoglobulin demand projected to grow at 7-8% annually through 2030, per industry reports. GC Biopharma holds a strong position in Asia as one of the largest plasma fractionators, competing with global leaders like CSL Behring and Grifols through cost-efficient operations and regulatory approvals. Its investments in recombinant tech position it for biosimilar opportunities in crowded markets.

For US investors, GC Biopharma's Nasdaq Global DR listing (if active) and partnerships with Western firms provide accessible entry to this niche, amid sector consolidation and supply chain diversification post-pandemic.

Why Green Cross Corp (GC Biopharma) matters for US investors

Green Cross Corp (GC Biopharma) offers US investors exposure to the fast-growing Asian biopharma market, where plasma product demand outpaces supply. With products registered in the US and potential for FDA approvals, it serves as a hedge against domestic shortages in immunoglobulins. Its KRX listing and global revenue streams tie performance to both Korean economic stability and worldwide biologics trends relevant to American healthcare spending.

Read more

Conclusion

Green Cross Corp (GC Biopharma) maintains a solid foundation in plasma-derived therapies and vaccines, with ongoing capacity expansions supporting revenue growth. While navigating global supply challenges, its strategic focus on high-demand biologics underscores long-term potential in biopharma. US investors monitor its international footprint and product pipeline for broader market insights. Market conditions remain dynamic, warranting close observation of quarterly updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.